Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibα glycoprotein | ||
| dc.conicet.organizacion | Universidade Estadual do Ceará | |
| dc.conicet.organizacion | Universidade Estadual do Ceará | |
| dc.conicet.organizacion | Universidade Estadual do Ceará | |
| dc.conicet.organizacion | Universidade Estadual do Ceará | |
| dc.conicet.organizacion | Universidade Estadual do Ceará | |
| dc.conicet.organizacion | Butantan Institute | |
| dc.conicet.organizacion | Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental | |
| dc.conicet.organizacion | Butantan Institute | |
| dc.contributor.author | Ferreira, M. A. D. | |
| dc.contributor.author | Do Nascimento, N. R. F. | |
| dc.contributor.author | De Sousa, C. M. | |
| dc.contributor.author | Pessoa, O. D. L. | |
| dc.contributor.author | De Lemos, T. L. G. | |
| dc.contributor.author | Ventura, J. S. | |
| dc.contributor.author | Schattner, Mirta Ana | |
| dc.contributor.author | Chudzinski Tavassi, A. M. | |
| dc.date.issued | 2008-07 | |
| dc.description.abstract | Background and purpose: Oncocalyxone A (OncoA) has a concentration- dependent anti-platelet activity. The present study aimed to further understand the mechanisms related to this effect. Experimental approach: Human platelet aggregation was measured by means of a turbidimetric method. OncoA (32-256 μM) was tested against several platelet-aggregating agents, such as adenosine diphosphate (ADP), collagen, arachidonic acid (AA), ristocetin and thrombin. Key results: OncoA completely inhibited platelet aggregation with a calculated mean inhibitory concentration (IC 50-μM) of 122 for ADP, 161 for collagen, 159 for AA, 169 for ristocetin and 85 for thrombin. The anti-aggregatory activity of OncoA was not inhibited by 1H-[1,2,4]oxadiazolo[4, 3-a]quinoxalin-1-one (ODQ). OncoA, at a concentration that caused no significant anti-aggregatory activity, potentiated sodium nitroprusside (SNP) anti-aggregatory activity (18.8±2.9%-SNP vs 85.0±8.2%-SNP+OncoA). The levels of nitric oxide (NO) or cAMP were not altered by OncoA while cGMP levels were increased more than 10-fold by OncoA in resting or ADP-activated platelets. Flow cytometry revealed that OncoA does not interact with receptors for fibrinogen, collagen or P-selectin. Nevertheless, OncoA decreased the binding of antibodies to GP Ibα, a glycoprotein that is related both to von Willebrand factor and to thrombin-induced platelet aggregation. Conclusion and implications: OncoA showed anti-aggregatory activity in platelets that was associated with increased cGMP levels, not dependent on NO and with blocking GP Ibα glycoprotein. This new mechanism has the prospect of leading to new anti-thrombotic drugs. © 2008 Nature Publishing Group All rights reserved. | es |
| dc.description.fil | Fil: Ferreira, M. A. D.. Universidade Estadual do Ceará; Brasil | |
| dc.description.fil | Fil: Do Nascimento, N. R. F.. Universidade Estadual do Ceará; Brasil | |
| dc.description.fil | Fil: De Sousa, C. M.. Universidade Estadual do Ceará; Brasil | |
| dc.description.fil | Fil: Pessoa, O. D. L.. Universidade Estadual do Ceará; Brasil | |
| dc.description.fil | Fil: De Lemos, T. L. G.. Universidade Estadual do Ceará; Brasil | |
| dc.description.fil | Fil: Ventura, J. S.. Butantan Institute; Brasil | |
| dc.description.fil | Fil: Schattner, Mirta Ana. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Medicina Experimental. Academia Nacional de Medicina de Buenos Aires. Instituto de Medicina Experimental; Argentina | |
| dc.description.fil | Fil: Chudzinski Tavassi, A. M.. Butantan Institute; Brasil | |
| dc.format | application/pdf | es |
| dc.identifier.citation | Ferreira, M. A. D.; Do Nascimento, N. R. F.; De Sousa, C. M.; Pessoa, O. D. L.; De Lemos, T. L. G.; et al.; Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibα glycoprotein; Wiley Blackwell Publishing, Inc; British Journal of Pharmacology; 154; 6; 7-2008; 1216-1224 | es |
| dc.identifier.institucional | CONICET | |
| dc.identifier.issn | 0007-1188 | es |
| dc.identifier.repo | CONICET Digital | |
| dc.identifier.uri | http://hdl.handle.net/11336/56619 | |
| dc.journal.ciudad | Londres | es |
| dc.journal.number | 6 | es |
| dc.journal.pagination | 1216-1224 | es |
| dc.journal.pais | Reino Unido | es |
| dc.journal.title | British Journal of Pharmacology | es |
| dc.journal.volume | 154 | es |
| dc.language.iso | eng | es |
| dc.publisher | Wiley Blackwell Publishing, Inc | es |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/doi/https://dx.doi.org/10.1038/bjp.2008.199 | |
| dc.relation.alternativeid | info:eu-repo/semantics/altIdentifier/url/https://bpspubs.onlinelibrary.wiley.com/doi/abs/10.1038/bjp.2008.199 | |
| dc.rights | info:eu-repo/semantics/openAccess | * |
| dc.rights.uri | https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ | * |
| dc.subject | Antiplatelet Activity | es |
| dc.subject | Auxemma Oncocalyx | es |
| dc.subject | Human Platelets | es |
| dc.subject | Oncocalyxone | es |
| dc.subject | Quinones | es |
| dc.subject.classification | Medicina Critica y de Emergencia | es |
| dc.subject.classification | Medicina Clínica | es |
| dc.subject.classification | CIENCIAS MÉDICAS Y DE LA SALUD | es |
| dc.title | Oncocalyxone A inhibits human platelet aggregation by increasing cGMP and by binding to GP Ibα glycoprotein | es |
| dc.type | info:eu-repo/semantics/article | |
| dc.type | info:ar-repo/semantics/artículo | |
| dc.type | info:eu-repo/semantics/publishedVersion | |
Archivos
Bloque original
Cargando...
- Nombre:
- CONICET_Digital_Nro.e6dcd94c-8ad6-4ac5-9bd7-a48aad3ec5ab_A.pdf
- Tamaño:
- 276.43 KB
- Formato:
- Adobe Portable Document Format